NOVAVAX INC
NVAX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NVAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NVAX
Novavax Inc. is a biotechnology company focused on developing vaccines using its recombinant protein nanoparticle technology and Matrix-M adjuvant, transitioning from a COVID-19-focused commercial entity to a partnership-driven R&D organization.
Key risk: Funding uncertainty
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 11 clinical trials for NOVAVAX INC.
Novavax Inc. is a biotechnology company focused on developing vaccines using its recombinant protein nanoparticle technology and Matrix-M adjuvant, transitioning from a COVID-19-focused commercial entity to a partnership-driven R&D organization.
- Novavax's platform features recombinant protein-based nanoparticle technology and Matrix-M adjuvant [sec_mda · as of 2025-11-06].
- The company achieved all $225 million in potential milestones for its Sanofi partnership in 2025 [sec · filed 2026-04-27].
- As of June 30, 2026, Novavax reported cash and equivalents of $196.0M, total revenue of $56.7M, and a net loss of $53.4M [sec].
- The company has an early-stage pipeline including candidates for C. diff, varicella-zoster virus, pandemic flu, and RSV combination [sec · filed 2025-04-29].
- Novavax reduced current liabilities by $1.3 billion over the last two years as of April 2025 [sec · filed 2025-04-29].
What works
- Novavax has a differentiated technology platform with recombinant protein nanoparticles and Matrix-M adjuvant, which is being explored for multiple applications including oncology [sec · filed 2026-04-27].
- The company successfully executed its Sanofi partnership, achieving all $225 million in potential milestones in 2025 [sec · filed 2026-04-27].
- Novavax has reduced current liabilities by $1.3 billion over two years, improving its financial structure [sec · filed 2025-04-29].
- The company is advancing a diversified early-stage pipeline beyond COVID-19, including C. diff, VZV, pandemic flu, and RSV combination [sec · filed 2025-04-29].
What to weigh
- Novavax reported a net loss of $53.4M for the six months ended June 30, 2026, compared to net income in the prior year period, primarily due to decreased total revenue [sec_mda · as of 2026-08-06].
- The company has negative shareholders' equity of -$127.8M as of June 30, 2026 [sec].
- Novavax faces uncertainty in obtaining adequate additional funding to maintain operations and fund further development [sec · filed 2025-04-29].
- The company has not received a Biologics License Application (BLA) from the U.S. FDA for its COVID-19 vaccine, relying on Emergency Use Authorization [sec · filed 2025-04-29].
From the filings
Quoted directly from source documents.
Novavax's technology platform includes recombinant protein nanoparticles and Matrix-M adjuvant.
“The differentiated platform features our recombinant protein-based nanoparticle technology and unique Matrix-M adjuvant.”
SEC MD&A · November 6, 2025
Novavax achieved all $225 million in potential milestones for its Sanofi partnership in 2025.
“we achieved all $225 million in potential milestones for our Sanofi partnership”
SEC filings · April 27, 2026
Novavax reduced current liabilities by $1.3 billion over two years.
“We improved our financial strength by reducing current liabilities by $1.3 billion over the last two years.”
SEC filings · April 29, 2025
Risks & what to watch (4)›
Key risks
- Funding uncertainty — Novavax may need additional funding to maintain operations and develop its pipeline, and such funding may not be available on acceptable terms [sec · filed 2025-04-29].
- Revenue decline — Net loss increased due to decreased total revenue in the six months ended June 30, 2026, compared to the prior year [sec_mda · as of 2026-08-06].
- Regulatory hurdles — The company has not received a BLA from the U.S. FDA for its COVID-19 vaccine, relying on EUA [sec · filed 2025-04-29].
- Partnership dependency — Success depends on executing the Sanofi partnership and forging additional partnerships, which may face challenges [sec · filed 2025-04-29].
What to watch
- Progress on early-stage pipeline candidates (C. diff, VZV, RSV) and phase 1 go/no-go decisions expected in early 2026 [sec · filed 2026-04-27].
- Ability to secure additional partnerships beyond Sanofi to leverage the technology platform [sec · filed 2026-04-27].
- Revenue trends from product sales, milestones, and royalties, given the decline in total revenue in 2026 [sec_mda · as of 2026-08-06].
- Cash runway and any additional financing activities, as cash and equivalents were $196.0M as of June 30, 2026 [sec].
Sources: SEC filings · SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run NOVAVAX INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available NOVAVAX INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
29.3 months
OCF -$73M · Net income -$53M
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
258
Total value held
$995.3M
| Holder | Shares | Value |
|---|---|---|
| shah capital management | 14,845,097 | $120.8M |
| vanguard capital management llc | 14,260,294 | $116.1M |
| blackrock, inc. | 12,844,319 | $104.6M |
| state street corp | 8,970,518 | $73.0M |
| d. e. shaw & co., inc. | 8,094,658 | $65.9M |
| vanguard portfolio management llc | 7,151,625 | $58.2M |
| bank of america corp /de/ | 6,637,213 | $54.0M |
| geode capital management, llc | 3,898,413 | $31.7M |
| millennium management llc | 3,875,045 | $31.5M |
| coatue management llc | 3,836,986 | $31.2M |
Showing top 10 of 258 institutional holders of NOVAVAX INC. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 30.3%
- Days to cover
- 15.6
- Shares short
- 49,475,862
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NVAX short interestGovernance
Frequently asked questions
What is the AI investment thesis for NOVAVAX INC?
Novavax Inc. is a biotechnology company focused on developing vaccines using its recombinant protein nanoparticle technology and Matrix-M adjuvant, transitioning from a COVID-19-focused commercial entity to a partnership-driven R&D organization.
What is NOVAVAX INC's lead drug candidate?
NOVAVAX INC's most advanced tracked candidate is cic (Phase 3) for COVID-19.
Who is the CEO of NOVAVAX INC?
Mr. John Charles Jacobs M.B.A. is the chief executive officer of NOVAVAX INC (NVAX).
Where is NOVAVAX INC headquartered?
NOVAVAX INC (NVAX) is headquartered in Gaithersburg, MD, United States.
What therapeutic areas does NOVAVAX INC focus on?
NOVAVAX INC develops therapies across Oncology, Immunology, Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.